Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research (NASDAQ:AMRI)

Albany Molecular Research logoAlbany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMRI
  • CUSIP: N/A
  • Web: www.amriglobal.com
Capitalization:
  • Market Cap: $933.57 million
  • Outstanding Shares: 41,604,000
Average Prices:
  • 50 Day Moving Avg: $21.68
  • 200 Day Moving Avg: $17.79
  • 52 Week Range: $13.01 - $22.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.09
  • P/E Growth: 1.79
Sales & Book Value:
  • Annual Revenue: $628.69 million
  • Price / Sales: 1.44
  • Book Value: $7.13 per share
  • Price / Book: 3.05
Profitability:
  • EBIDTA: $71.8 million
  • Net Margins: -11.26%
  • Return on Equity: 11.97%
  • Return on Assets: 3.23%
Debt:
  • Debt-to-Equity Ratio: 2.05%
  • Current Ratio: 2.31%
  • Quick Ratio: 1.26%
Misc:
  • Average Volume: 1.36 million shs.
  • Beta: 1.18
  • Short Ratio: 2.51
 
Frequently Asked Questions for Albany Molecular Research (NASDAQ:AMRI)

What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research, Inc. (NASDAQ:AMRI) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. The company earned $163.80 million during the quarter, compared to analysts' expectations of $161.43 million. Albany Molecular Research had a negative net margin of 11.26% and a positive return on equity of 11.97%. The firm's revenue was up 55.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.07 EPS. View Albany Molecular Research's Earnings History.

When will Albany Molecular Research make its next earnings announcement?

Albany Molecular Research is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Albany Molecular Research.

What guidance has Albany Molecular Research issued on next quarter's earnings?

Albany Molecular Research updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $1.08-1.20 for the period, compared to the Thomson Reuters consensus estimate of $1.16. The company issued revenue guidance of $710-740 million, compared to the consensus revenue estimate of $720.68 million.

Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?

4 equities research analysts have issued 12-month target prices for Albany Molecular Research's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Albany Molecular Research's share price to reach $18.00 in the next twelve months. View Analyst Ratings for Albany Molecular Research.

Who are some of Albany Molecular Research's key competitors?

Who are Albany Molecular Research's key executives?

Albany Molecular Research's management team includes the folowing people:

  • William S. Marth, President, Chief Executive Officer, Director
  • Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
  • Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
  • Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
  • Milton Boyer, Senior Vice President - Drug Product Manufacturing
  • Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
  • George Svokos, Chief Commercial Officer and Senior Vice President, API
  • Jimmy Wang Ph.D., Chief Information Officer
  • Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
  • David H. Deming, Director

Who owns Albany Molecular Research stock?

Albany Molecular Research's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Chicago Capital Management LLC (2.37%), AMI Asset Management Corp (1.77%), Longfellow Investment Management Co. LLC (0.66%), Fisher Asset Management LLC (0.44%), Kassirer Asset Management Corp (0.44%) and Russell Investments Group Ltd. (0.39%). Company insiders that own Albany Molecular Research stock include Ambra Constance M D, Anthony J Maddaluna, George Svokos, Kevin Oconnor, Lori M Henderson, Steven R Hagen and William S Marth. View Institutional Ownership Trends for Albany Molecular Research.

Who sold Albany Molecular Research stock? Who is selling Albany Molecular Research stock?

Albany Molecular Research's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Cohen Lawrence B and Atria Investments LLC. Company insiders that have sold Albany Molecular Research stock in the last year include Lori M Henderson and Steven R Hagen. View Insider Buying and Selling for Albany Molecular Research.

Who bought Albany Molecular Research stock? Who is buying Albany Molecular Research stock?

Albany Molecular Research's stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital Management LLC, Longfellow Investment Management Co. LLC, Kassirer Asset Management Corp, Fisher Asset Management LLC, AMI Asset Management Corp, ING Groep NV, Round Table Services LLC and Great West Life Assurance Co. Can. Company insiders that have bought Albany Molecular Research stock in the last two years include Anthony J Maddaluna, George Svokos and William S Marth. View Insider Buying and Selling for Albany Molecular Research.

How do I buy Albany Molecular Research stock?

Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albany Molecular Research's stock price today?

One share of Albany Molecular Research stock can currently be purchased for approximately $21.72.


MarketBeat Community Rating for Albany Molecular Research (NASDAQ AMRI)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $18.00 (17.13% downside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017First AnalysisDowngradeOverweight -> Equal WeightLowView Rating Details
6/8/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralLowView Rating Details
6/6/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/11/2017Morgan StanleyDowngradeOverweight -> Equal Weight$18.00HighView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Albany Molecular Research (NASDAQ:AMRI)
Earnings by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Earnings History by Quarter for Albany Molecular Research (NASDAQ AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017$0.29N/AView Earnings Details
5/9/2017Q1 2017$0.12$0.13$161.43 million$163.80 millionViewListenView Earnings Details
2/21/2017Q416$0.48$0.34$221.30 million$191.30 millionViewListenView Earnings Details
11/8/2016Q316$0.13$0.17$160.75 million$151.70 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.19$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.16($0.02)$71.00 million$62.47 millionViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
2017 EPS Consensus Estimate: $1.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.11$0.11$0.11
Q2 20172$0.23$0.28$0.26
Q3 20172$0.15$0.19$0.17
Q4 20172$0.42$0.54$0.48
Q1 20181$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Albany Molecular Research (NASDAQ:AMRI)
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 76.19%
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Anthony J MaddalunaDirectorBuy1,518$16.46$24,986.28View SEC Filing  
11/30/2016Steven R HagenSVPSell9,000$16.71$150,390.00View SEC Filing  
11/16/2016Lori M HendersonSVPSell6,000$17.00$102,000.00View SEC Filing  
11/10/2016Steven R HagenSVPSell785$16.79$13,180.15View SEC Filing  
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Albany Molecular Research (NASDAQ:AMRI)
Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
Source:
DateHeadline
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Expected to Announce Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 27 at 3:05 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (NASDAQ:AMRI) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:12 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Expected to Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - July 25 at 9:20 AM
finance.yahoo.com logoAlbany Molecular Research, Inc. -- Moody's assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany Molecular Research, Inc.)
finance.yahoo.com - July 19 at 5:02 PM
finance.yahoo.com logoThe Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI
finance.yahoo.com - July 17 at 4:10 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
finance.yahoo.com - July 13 at 4:35 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular Research, Inc. - AMRI
finance.yahoo.com - July 5 at 9:00 PM
americanbankingnews.com logo Analysts Anticipate Albany Molecular Research, Inc. (AMRI) Will Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 1 at 10:04 AM
bizjournals.com logoAMRI chief gives a billion reasons why the company is about to be sold
www.bizjournals.com - July 1 at 1:56 AM
finance.yahoo.com logoAMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group and GTCR's Proposed Acquisition of AMRI
finance.yahoo.com - June 29 at 4:55 PM
americanbankingnews.com logo Brokerages Expect Albany Molecular Research, Inc. (AMRI) to Announce $0.23 EPS
www.americanbankingnews.com - June 29 at 7:48 AM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders - AMRI
finance.yahoo.com - June 20 at 4:06 PM
finance.yahoo.com logoSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI
finance.yahoo.com - June 15 at 10:12 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - June 13 at 8:32 PM
finance.yahoo.com logoThe Law Offices of Vincent Wong Reminds Investors of an Investigation of Albany Molecular Research, Inc. in Connection with the Sale of the Company to GTCR LLC and The Carlyle Group
finance.yahoo.com - June 13 at 3:31 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Lowered to Equal Weight at First Analysis
www.americanbankingnews.com - June 12 at 6:06 PM
finance.yahoo.com logoWeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Interest of AMRI Shareholders
finance.yahoo.com - June 9 at 3:50 PM
finance.yahoo.com logoThe Law Offices of Vincent Wong Notifies Investors of an Investigation of Albany Molecular Research, Inc. in Connection with the Sale of the Company to GTCR LLC and The Carlyle Group
finance.yahoo.com - June 9 at 3:50 PM
finance.yahoo.com logoSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc - AMRI
finance.yahoo.com - June 9 at 3:50 PM
finance.yahoo.com logoETFs with exposure to Albany Molecular Research, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 4:13 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Cut to "Neutral" at JPMorgan Chase & Co.
www.americanbankingnews.com - June 8 at 2:52 PM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc.
finance.yahoo.com - June 7 at 8:41 PM
finance.yahoo.com logoAlbany Molecular Research, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Merger with The Carlyle Group
finance.yahoo.com - June 7 at 3:39 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders
finance.yahoo.com - June 7 at 3:39 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - June 7 at 3:39 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Expected to Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - June 7 at 1:06 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders
finance.yahoo.com - June 7 at 1:34 AM
finance.yahoo.com logoALBANY MOLECULAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albany Molecular Research, Inc.
finance.yahoo.com - June 7 at 1:34 AM
seekingalpha.com logoCarlyle Group takes out Albany Molecular Research for $21.75/share; +9% premarket
seekingalpha.com - June 6 at 8:34 PM
News IconGTCR and Carlyle Group are buying Albany Molecular Research for $922 million
www.businessinsider.com - June 6 at 8:34 PM
streetinsider.com logoAlbany Molecular Research (AMRI) Agrees to Be Acquired by The Carlyle Group and GTCR for $21.75/Share
www.streetinsider.com - June 6 at 8:34 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI
finance.yahoo.com - June 6 at 8:34 PM
finance.yahoo.com logoALBANY MOLECULAR RESEARCH, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
finance.yahoo.com - June 6 at 3:31 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Cut to "Market Perform" at William Blair
www.americanbankingnews.com - June 6 at 1:40 PM
finance.yahoo.com logoAMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoAlbany Molecular Research to be taken private for $21.75 a share in cash
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoEquity firms in talks to acquire this public company in Albany
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoAlbany Molecular (AMRI) Alert: J&W Investigates Price and Process of Proposed Sale of Albany Molecular Research, Inc.; Is $21.75 a Fair Price?
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoAlbany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoGTCR, Carlyle to buy contract research firm Albany Molecular
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logoWhy Albany Molecular Is Actually Getting a Very Good Premium
finance.yahoo.com - June 6 at 10:46 AM
finance.yahoo.com logo[$$] Carlyle, GTCR to Acquire Contract-Drug Manufacturer
finance.yahoo.com - June 6 at 10:46 AM
reuters.com logoExclusive: GTCR, Carlyle in talks to acquire Albany Molecular Research - sources
www.reuters.com - June 5 at 6:25 PM
americanbankingnews.com logoZacks: Analysts Anticipate Albany Molecular Research, Inc. (AMRI) Will Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - June 5 at 9:36 AM
finance.yahoo.com logoAMRI to Present at Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 4:44 PM
bizjournals.com logoGlobal Contract Research Outsourcing - Services
www.bizjournals.com - May 29 at 3:55 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Albany Molecular Research, Inc.'s Q2 2017 Earnings (AMRI)
www.americanbankingnews.com - May 26 at 8:02 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Receives "Outperform" Rating from William Blair
www.americanbankingnews.com - May 23 at 11:48 PM
americanbankingnews.com logoFirst Analysis Analysts Cut Earnings Estimates for Albany Molecular Research, Inc. (AMRI)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Forecasted to Earn Q3 2017 Earnings of $0.19 Per Share
www.americanbankingnews.com - May 16 at 8:18 AM

Social

Chart

Albany Molecular Research (AMRI) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff